Baxter International Inc. said it has expanded a deal with Japan’s largest drug maker to bring its cell-based vaccine technology to that country.
The Deerfield-based medical product giant said terms of the agreement with Osaka, Japan-based Takeda Pharmaceutical Company Limited call for “Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.”
Baxter’s technology makes vaccines without the use of eggs, which can be more time consuming and delay production though egg-based vaccine technology has been effective and around for decades.
Speficic financial terms of the deal, which includes Takeda making payments to Baxter, were not disclosed. Neither company expects to revise its 2010 earnings guidance based on the deal.
bjapsen@tribune.com
